Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 14
2003 14
2004 11
2005 14
2006 11
2007 14
2008 16
2009 13
2010 18
2011 19
2012 19
2013 20
2014 25
2015 23
2016 30
2017 21
2018 27
2019 22
2020 25
2021 29
2022 30
2023 19

Text availability

Article attribute

Article type

Publication date

Search Results

372 results

Results by year

Filters applied: . Clear all
Page 1
PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes.
Aroda VR, Rosenstock J, Terauchi Y, Altuntas Y, Lalic NM, Morales Villegas EC, Jeppesen OK, Christiansen E, Hertz CL, Haluzík M; PIONEER 1 Investigators. Aroda VR, et al. Among authors: terauchi y. Diabetes Care. 2019 Sep;42(9):1724-1732. doi: 10.2337/dc19-0749. Epub 2019 Jun 11. Diabetes Care. 2019. PMID: 31186300
Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A subgroup analysis by baseline variables in the PIONEER 9 and PIONEER 10 trials.
Yabe D, Deenadayalan S, Horio H, Kaneto H, Jensen TB, Terauchi Y, Yamada Y, Inagaki N. Yabe D, et al. Among authors: terauchi y. J Diabetes Investig. 2022 Jun;13(6):975-985. doi: 10.1111/jdi.13764. Epub 2022 Mar 3. J Diabetes Investig. 2022. PMID: 35112504 Free PMC article. Clinical Trial.
Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial.
Ueki K, Sasako T, Okazaki Y, Kato M, Okahata S, Katsuyama H, Haraguchi M, Morita A, Ohashi K, Hara K, Morise A, Izumi K, Ishizuka N, Ohashi Y, Noda M, Kadowaki T; J-DOIT3 Study Group. Ueki K, et al. Lancet Diabetes Endocrinol. 2017 Dec;5(12):951-964. doi: 10.1016/S2213-8587(17)30327-3. Epub 2017 Oct 24. Lancet Diabetes Endocrinol. 2017. PMID: 29079252 Clinical Trial.
[PPAR and diabetes].
Terauchi Y, Kadowaki T. Terauchi Y, et al. Nihon Rinsho. 2005 Apr;63(4):623-9. Nihon Rinsho. 2005. PMID: 15828230 Review. Japanese.
372 results